A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Blood Advances Année : 2023

A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis.

1 Memorial Sloane Kettering Cancer Center [New York]
2 UCLH - University College London Hospitals NHS Foundation Trust [London, UK]
3 MCW - Medical College of Wisconsin [Milwaukee]
4 UPV - Universitat Politècnica de València = Universitad Politecnica de Valencia = Polytechnic University of Valencia
5 Mayo Clinic
6 Imperial College London
7 Massachusetts General Hospital [Boston]
8 University Hospitals Bristol
9 MUMC - Maastricht University Medical Centre
10 Sarah Cannon Research Institute [Nashville, Tennessee]
11 HIUNJ - Hospital Infantil Universitario Niño Jesús
12 Princess Margaret Hospital
13 City of Hope Comprehensive Cancer Center [Duarte]
14 Mayo Clinic [Rochester]
15 Cleveland State University
16 Jefferson (Philadelphia University + Thomas Jefferson University)
17 Emory University [Atlanta, GA]
18 URMC - University of Rochester Medical Center
19 University of Miami
20 The Ottawa Hospital
21 Vanderbilt University Medical Center [Nashville]
22 Houston Methodist Hospital [Houston, TX, USA]
23 UNIBE - Universität Bern / University of Bern
24 Penn State Health Milton S. Hershey Medical Center
25 JHU - Johns Hopkins University
26 Dana-Farber Cancer Institute [Boston]
27 KFSHRC - King Faisal Specialist Hospital and Resarch Centre [Riyadh, Saudi Arabia]
28 University of Virginia
29 Mayo Clinic [Jacksonville]
30 UK - University of Kentucky
31 University of Michigan Medical School [Ann Arbor]
32 University of Maryland [Baltimore]
33 Rush University Medical Center [Chicago]
34 H. Lee Moffitt Cancer Center and Research Institute
35 Dokkyo Medical University
36 FHCRC - Fred Hutchinson Cancer Research Center [Seattle]
37 The University of Texas M.D. Anderson Cancer Center [Houston]
38 MCMCC - Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
39 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
40 LIRIC - Lille Inflammation Research International Center - U 995
Jeanne M. Palmer
  • Fonction : Auteur
Leo F. Verdonck
  • Fonction : Auteur
Jeffrey J. Pu
  • Fonction : Auteur
David A. Rizzieri
  • Fonction : Auteur
Michael R. Grunwald
  • Fonction : Auteur


To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in the United States (the Center for International Blood and Marrow Transplant Research [CIBMTR] cohort). A Cox multivariable model was used to identify factors prognostic of mortality. A weighted score using these factors was assigned to patients who received transplantation in Europe (the European Bone Marrow Transplant [EBMT] cohort; n = 623). Patient age >50 years (hazard ratio [HR], 1.39; 95% confidence interval [CI], 0.98-1.96), and HLA-matched unrelated donor (HR, 1.29; 95% CI, 0.98-1.7) were associated with an increased hazard of death and were assigned 1 point. Hemoglobin levels <100 g/L at time of transplantation (HR, 1.63; 95% CI, 1.2-2.19) and a mismatched unrelated donor (HR, 1.78; 95% CI, 1.25-2.52) were assigned 2 points. The 3-year overall survival (OS) in patients with a low (1-2 points), intermediate (3-4 points), and high score (5 points) were 69% (95% CI, 61-76), 51% (95% CI, 46-56.4), and 34% (95% CI, 21-49), respectively (P < .001). Increasing score was predictive of increased transplant-related mortality (TRM; P = .0017) but not of relapse (P = .12). The derived score was predictive of OS (P < .001) and TRM (P = .002) but not of relapse (P = .17) in the EBMT cohort as well. The proposed system was prognostic of survival in 2 large cohorts, CIBMTR and EBMT, and can easily be applied by clinicians consulting patients with MF about the transplantation outcomes.
Fichier principal
Vignette du fichier
blooda_adv-2023-009886-main.pdf (442.79 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04520162 , version 1 (25-03-2024)


Paternité - Pas d'utilisation commerciale - Pas de modification



Roni Tamari, Donal P. Mclornan, Kwang Woo Ahn, Noel Estrada-Merly, Juan Carlos Hernandez-Boluda, et al.. A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis.. Blood Advances, 2023, Blood Advances, ⟨10.1182/bloodadvances.2023009886⟩. ⟨hal-04520162⟩


0 Consultations
0 Téléchargements



Gmail Facebook X LinkedIn More